Results 1 to 10 of about 1,100 (107)
Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis [PDF]
Frontiers in Pharmacology, 2021 Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Dan Li +8 more
doaj +3 more sources
Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae
Emerging Infectious Diseases, 2023 We identified a novel ceftazidime/avibactam resistance mechanism in sequence type 11 Klebsiella pneumoniae carbapenemase 2–producing K. pneumoniae.
Qiaozhen Cui +6 more
doaj +2 more sources
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination [PDF]
Drugs, 2013 Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. This review summarizes the existing data published for ceftazidime-avibactam, including relevant chemistry, mechanisms of action and resistance, microbiology ...
George G Zhanel +2 more
exaly +3 more sources
Revista Española de Quimioterapia, 2021 Ceftazidime is a 3rd generation cephalosporin active against Pseudomonas aeruginosa. Avibactam is an inhibitor of class A, C and some class D β-lactamases. The antibacterial spectrum of ceftazidime-avibactam covers 95% of P. aeruginosa isolates and >99% of enterobacteria, including strains carrying extended-spectrum β-lactamases (ESBLs).
Matesanz, Mayra, Mensa, José
openaire +2 more sources
Ceftazidime-avibactam in ceftazidime-resistant infections [PDF]
The Lancet Infectious Diseases, 2016 One of the important causes of the development of resistance to β-lactam drugs is their overuse. β-lactamase inhibitors have been combined with many β-lactam drugs to resume their efficacy since the emergence of multidrugresistant organisms. Yahuda Carmeli and colleagues recommended the combination of ceftazidimeavibactam as a potential alternative to ...
Yehuda, Carmeli +4 more
openaire +5 more sources
In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
Frontiers in Microbiology, 2021 Ceftazidime/avibactam is an important treatment option for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp), however, resistance can emerge during treatment.
Yanqin Huang +8 more
doaj +1 more source
Antibiotics, 2021 β-lactam–avibactam combinations have been proposed as carbapenem-sparing therapies, but little data exist on their in vitro activities in infections with high bacterial inocula.
Moonsuk Bae +12 more
doaj +1 more source
Antibiotics, 2021 Ceftazidime/avibactam uniquely demonstrates activity against both KPC and OXA-48-like carbapenemase-expressing Enterobacterales. Clinical resistance to ceftazidime/avibactam in KPC-producers was foreseen in in-vitro resistance studies.
Snehal Palwe +5 more
doaj +1 more source
BMC Microbiology, 2021 Background Resistance to ceftazidime-avibactam was reported, and it is important to investigate the mechanisms of ceftazidime/avibactam resistance in K. pneumoniae with mutations in bla KPC. Results We report the mutated bla KPC is not the only mechanism
Lingxiao Sun +4 more
doaj +1 more source
International Journal of Infectious Diseases, 2021 Introduction: Antimicrobial treatments for carbapenem-resistant Enterobacteriaceae (CRE) bacteremia are limited, with colistin-based regimens being a primary therapy. Ceftazidime–avibactam is an emerging treatment for various CRE infections.
Hakeam A. Hakeam +5 more
doaj +1 more source